Yazdan Yazdanpanah

Learn More
Citation for published version: Rahier, JF, Magro, F, Abreu, C, Armuzzi, A, Ben-Horin, S, Chowers, Y, Cottone, M, de Ridder, L, Doherty, G, Ehehalt, R, Esteve, M, Katsanos, K, Lees, CW, Macmahon, E, Moreels, T, Reinisch, W, Tilg, H, Tremblay, L, Veereman-Wauters, G, Viget, N, Yazdanpanah, Y, Eliakim, R, Colombel, JF & on behalf of the European Crohn's and(More)
Despite recent advances in the management of hepatitis and HIV co-infection, there is no clear consensus among hepatology, infectious diseases and virology experts on treatment of co-infections and patient management. This encouraged the organisation of a European Consensus Conference to review current knowledge on the treatment of chronic hepatitis B and C(More)
BACKGROUND As antiretroviral therapy is increasingly used in settings with limited resources, key questions about the timing of treatment and use of diagnostic tests to guide clinical decisions must be addressed. METHODS We assessed the cost-effectiveness of treatment strategies for a cohort of adults in Côte d'Ivoire who were infected with the human(More)
Understanding the natural history of human immunodeficiency virus type 1 (HIV-1) and opportunistic infections in sub-Saharan Africa is necessary to optimize strategies for the prophylaxis and treatment of opportunistic infections and to understand the likely impact of antiretroviral therapy. We undertook a systematic review of the literature on HIV-1(More)
OBJECTIVE To determine the component costs of care to optimize treatment with limited resources. DESIGN We used the Cost-Effectiveness of Preventing AIDS Complications Model of HIV disease and treatment to project life expectancy and both undiscounted and discounted lifetime costs (2010 €). METHODS We determined medical resource utilization among(More)
J.F. Rahier ⁎, S. Ben-Horin, Y. Chowers, C. Conlon, P. De Munter, G. D'Haens, E. Domènech, R. Eliakim, A. Eser, J. Frater, M. Gassull, M. Giladi, A. Kaser, M. Lémann, T. Moreels, A. Moschen, R. Pollok, W. Reinisch, M. Schunter, E.F. Stange, H. Tilg, G. Van Assche, N. Viget, B. Vucelic, A. Walsh, G. Weiss, Y. Yazdanpanah, Y. Zabana, S.P.L. Travis, J.F.(More)
Emerging health problems require rapid advice. We describe the development and pilot testing of a systematic, transparent approach used by the World Health Organization (WHO) to develop rapid advice guidelines in response to requests from member states confronted with uncertainty about the pharmacological management of avian influenza A (H5N1) virus(More)
BACKGROUND The introduction of 2 or 3 fully active drugs in human immunodeficiency virus (HIV)-infected patients receiving failing antiretroviral therapy is a key determinant of subsequent treatment efficacy. The aim of this study was to assess the safety and efficacy of a regimen containing raltegravir, etravirine, and darunavir/ritonavir for(More)
Because of the increasing use of immunosuppressive and biological drugs, the occurrence of opportunistic infections has become a key safety issue for patients with inflammatory bowel disease (IBD). Consequently, improvement of healthcare workers' knowledge of this domain is urgent. In this review, the preventive measures that would help to reduce the rate(More)
BACKGROUND Variables associated with the outcome of patients treated for prosthetic joint infections (PJIs) due to Staphylococcus aureus are not well known. METHODS The medical records of patients treated surgically for total hip or knee prosthesis infection due to S. aureus were reviewed. Remission was defined by the absence of local or systemic signs of(More)